AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAY 15 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Researchers in the U.S. found heptavalent CRM197 pneumococcal vaccine (PCV) as safe and effective as the meningococcal type C conjugate vaccine (MCV) for protecting low-birth-weight and preterm infants against invasive pneumococcal disease.
H. Shinefield of the Kaiser Permanente Vaccine Study Center, Oakland, California and colleagues followed 37,868 infants enrolled in a randomized double blind clinical trial to compare the safety, efficacy, and immunogenicity of the PCV and MCV. Of the total number of children, 1756 were identified as low birth weight (between 750 and 2500 g) and 4340 classified as preterm (32 to 38 weeks gestation). The timing of the immunizations was found to be similar among the groups.
Through telephone interviews, emergency department visits, and hospitalization records, Shinefield 's team determined the risk of invasive pneumococcal disease, incidence of vaccination side effects, and vaccine efficacy in low-birth-weight (LBW), normal birth weight (NBW), preterm (PT), and full term (FT) infants.
LBW infants were 2.6 times more likely than NBW infants to develop invasive pneumococcal diseases (p=0.03), while PT were 1.6 times more likely than FT infants to develop the disease (p=0.06) (Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and ...
Source: HighBeam Research, Pneumococcal conjugate vaccine safe for low-birth-weight and preterm...